In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
Bioplastic straws an unlikely savior for coral
In Florida, researchers have developed a novel solution to keeping young, vulnerable coral from being eaten by predatory fish: protective cages made from bioplastic...
Canadian rapper Drake photographed sporting biobased EVA slip ons from Kane
In Canada, “Hotline Bling” rapper Drake has been seen sporting pink biobased slip-on shoes designed by Kane.
Founded in 2020 by former Maverik Lacrosse CEO...
Sorry parents, fruit waste glitter is still a pain to clean up
In the United Kingdom, scientists at Cambridge University have developed biodegradable glitter made from nanocrystals of cellulose extracted from fruit waste.
The sustainable sparkle solution...